Tharimmune Inc (THAR)
0.3651
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
0.3651
0.00 (0.00%)
After-Hours: 20:00
Tharimmune SG&A Expense (Quarterly): 1.322M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.322M |
| December 31, 2023 | 1.538M |
| September 30, 2023 | 1.357M |
| June 30, 2023 | 1.334M |
| March 31, 2023 | 1.667M |
| December 31, 2022 | 1.083M |
| September 30, 2022 | 1.296M |
| June 30, 2022 | 1.181M |
| Date | Value |
|---|---|
| March 31, 2022 | 1.043M |
| December 31, 2021 | 0.1426M |
| September 30, 2021 | 0.228M |
| June 30, 2021 | 0.423M |
| March 31, 2021 | 0.5717M |
| December 31, 2020 | 0.3516M |
| September 30, 2020 | 0.159M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.1426M
Minimum
Dec 2021
1.667M
Maximum
Mar 2023
0.9131M
Average
1.083M
Median
Dec 2022
SG&A Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals Inc | 37.60M |
| Mirum Pharmaceuticals Inc | 45.64M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |
| iBio Inc | 2.961M |